Finance

Beta
Lists
6855:HKG
Ascentage Pharma Group International
HK$34.20
+3.01%
(+1.00) 1D
Jun 10, 4:09:06 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 6855...
Open
HK$33.80
High
HK$34.94
Low
HK$32.50
Mkt. cap
12.78B
Avg. vol.
2.57M
Volume
2.40M
52-wk high
HK$95.35
52-wk low
HK$32.50
EPS
-HK$4.04
No. of employees
767
Open
HK$33.80
High
HK$34.94
Low
HK$32.50
Mkt. cap
12.78B
Avg. vol.
2.57M
Volume
2.40M
52-wk high
HK$95.35
52-wk low
HK$32.50
EPS
-HK$4.04
No. of employees
767
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to 6855 in the past 3 months
Strong Buy
Buy
3
Hold
0
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for 6855 in the last 3 months.
Highest
Current HK$34.20
HK$89.00 (+160.23%)
Average
HK$73.10 (+113.74%)
Lowest
HK$59.09 (+72.78%)
News stories
From sources across the web
About Ascentage Pharma Group International
CEODajun Yang
Employees767
Founded2009
Headquarters-
SectorBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
116.85M
116.85M
170.21M
170.21M
Cost of goods sold
10.82M
10.82M
13.64M
13.64M
Cost of revenue
10.82M
10.82M
13.64M
13.64M
Research and development expenses
264.28M
264.28M
304.44M
304.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
118.74M
118.74M
181.22M
181.22M
Operating expense
383.02M
383.02M
485.67M
485.67M
Total operating expenses
393.84M
393.84M
499.31M
499.31M
Operating income
-276.99M
-276.99M
-329.10M
-329.10M
Other non operating income
-17.47M
-17.47M
-2.99M
-2.99M
EBT including unusual items
-292.66M
-292.66M
-325.37M
-325.37M
EBT excluding unusual items
-292.66M
-292.66M
-324.79M
-324.79M
Income tax expense
2.76M
2.76M
714.00K
714.00K
Effective tax rate
-0.94%
-0.94%
-0.22%
-0.22%
Other operating expenses
-
-
-
-
Net income
-295.38M
-295.38M
-326.00M
-326.00M
Net profit margin
-252.79%
-252.79%
-191.53%
-191.53%
Earnings per share
-
-
-
-
Interest and investment income
15.70M
15.70M
25.36M
25.36M
Interest expense
-13.90M
-13.90M
-13.14M
-13.14M
Net interest expenses
1.81M
1.81M
12.22M
12.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
-257.85M
-257.85M
-310.96M
-310.96M
Gain or loss from assets sale
-
-
-333.50K
-333.50K
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more